How Pediatric Exclusivity and Priority Review Vouchers Accelerate Rare Disease Drug Development

Why Pediatric Incentives Are Critical in Rare Disease Drug Development

Over 50% of rare diseases affect children, yet pediatric drug development often lags due to ethical complexities, limited commercial return, and small patient populations. To address this, the U.S. Food and Drug Administration (FDA) has introduced specific regulatory incentives to promote research in rare pediatric diseases, including Pediatric Exclusivity and the Rare Pediatric Disease Priority Review Voucher (PRV) program.

These mechanisms reward sponsors for conducting pediatric studies, accelerating access to life-saving therapies while offering tangible commercial and regulatory benefits. For sponsors developing orphan-designated or ultra-rare pediatric therapies, these programs can provide both strategic leverage and financial returns.

Pediatric Exclusivity: What It Is and How It Works

Authorized under the Best Pharmaceuticals for Children Act (BPCA), pediatric exclusivity is a 6-month extension of existing regulatory exclusivity (e.g., Orphan Drug Exclusivity, New Chemical Entity, or patent protection). This incentive is granted when a sponsor completes FDA-requested studies under a Written Request (WR) for pediatric use.

Key Points:

• Pediatric studies must address safety and/or efficacy in the relevant age group (neonates to adolescents)
• The studies must follow protocols outlined in the FDA’s Written Request
• Upon acceptance, 6 months is added to all forms of marketing exclusivity for that drug

This extension applies even if the pediatric indication is not ultimately approved, making it a powerful incentive for broader product lifecycle management.

Rare Pediatric Disease Priority Review Voucher (PRV): Overview and Eligibility

The PRV program rewards sponsors that develop treatments for serious or life-threatening rare pediatric diseases. Upon approval of a qualifying application, the sponsor receives a transferable voucher that entitles the holder to priority review (6-month review timeline) of a future drug or biologic application.

Eligibility Criteria:

• The disease must primarily affect individuals under 18 years old
• The condition must be rare (<200,000 patients in the U.S.)
• The drug must represent a new active ingredient (not a label extension)

Priority Review Vouchers are transferable and monetizable, with past transactions exceeding $100 million in value. For smaller biotech companies, selling a PRV can provide non-dilutive capital to fund additional trials.

Examples of Drugs Awarded Pediatric PRVs

Since its inception in 2012, the PRV program has accelerated the development of therapies for numerous pediatric rare diseases. Examples include:

• Vimizim (elosulfase alfa) for Morquio A syndrome – PRV sold for $67 million
• Luxturna (voretigene neparvovec) for inherited retinal dystrophy – PRV retained by sponsor
• Brineura (cerliponase alfa) for CLN2 Batten disease – PRV used for follow-up asset

The financial value of PRVs has supported clinical expansion, commercialization infrastructure, and investor confidence in otherwise high-risk pipelines.

Comparison: Pediatric Exclusivity vs Priority Review Voucher

Savvy sponsors often pursue both, especially when developing novel pediatric therapies with orphan designation and unmet need alignment.

Regulatory Considerations and Best Practices

To maximize benefit and ensure compliance:

• Engage the FDA early through a Pediatric Study Plan (PSP)
• Request Written Request documentation and negotiate feasible study designs
• For PRVs, ensure your target indication meets the statutory definition under Section 529 of the FD&C Act
• Include PRV language in the initial NDA/BLA cover letter

Sponsors should consult CDER’s Rare Diseases Program or CBER’s Office of Tissues and Advanced Therapies for guidance tailored to their product type (small molecule vs biologic vs gene therapy).

Commercial Implications and Funding Opportunities

Pediatric incentives offer not just regulatory advantages, but strategic financial benefits as well:

• 6-month exclusivity can translate to hundreds of millions in additional revenue for blockbuster drugs
• PRV sales provide immediate capital to advance other pipeline assets
• Investors view these incentives as de-risking mechanisms, often improving access to capital

In rare pediatric conditions with short survival timelines, these incentives also create urgency within the company—often speeding internal decision-making and resource allocation.

Case Study: Pediatric Exclusivity in a Spinal Muscular Atrophy (SMA) Drug

The developer of Spinraza (nusinersen) submitted post-marketing pediatric studies as requested by the FDA under BPCA. Upon completion, the FDA granted an additional 6 months of exclusivity, which extended the drug’s monopoly despite the presence of competing gene therapies. The additional time allowed for continued market leadership and justified pricing discussions with global payers.

Conclusion: Incentives That Make a Measurable Difference

Pediatric Exclusivity and Priority Review Vouchers are vital components of the rare pediatric drug development ecosystem. When strategically leveraged, they help sponsors recoup investment, fund innovation, and—most importantly—accelerate the delivery of therapies to the most vulnerable patient populations. As the regulatory landscape continues to evolve, these incentives remain key enablers for turning rare pediatric treatments into commercial and clinical realities.